SUMMARY By the direct immunofluorescence technique 19 liver biopsies were examined for the presence of the e-antigen associated with the hepatitis B virus infection. With the use of double incubation and blocking experiments with FITC and Rhodamine labelled antisera against hepatitis B core antigen and e-antigen, evidence is presented that the e-antigen is localised in the nuclei of the hepatocytes. We conclude that the e-antigen and the core antigen are not identical, although they are often present simultaneously in the nucleus of the hepatocyte.
It is well established that the e-antigen is closely associated with the hepatitis B virus infections (Nielsen et al., 1974) . However, the exact biological nature of the e-antigen and its intracellular localisation is still obscure.
Using direct immunofluorescence technique on liver sections Trepo et al. (1976) have demonstrated cytoplasmic binding of human anti-e serum samples. In contrast with this, we now have evidence for an intranuclear localisation of the e-antigen on the basis of double incubation studies with monospecific fluorescein-or rhodamine-labelled anti-HB,-, anti-HB,-and anti-e-conjugates.
Methods

PATIENTS
Liver biopsies from 13 patients with HB,Ag and e-antigen positive chronic active hepatitis (CAH) The e-antigen was determined by the Ouchterlony technique as described by Espmark (1972a, 1972b) . Each positive sample was tested for identity with reference sera previously described (Nielsen et al., 1974; Hess et al., 1977) .
Immunofluorescence studies were performed to demonstrate HBsAg, HB,Ag and e-antigen by the direct immunofluorescence technique. The conjugates were self-prepared and purified according to a method described elsewhere (Arnold and Mayersbach, 1972; Arnold, 1976) . The following conjugates were used in this study: (1) human anti-HB,-FITC (titre (RIA): 1:4096, mol F/P-ratio 2 8; negative for anti-HB, and anti-e); (2) human anti-HB,-FITC (titre (IAHA): 1 :64 000, mol F/P-ratio 2-5; negative for anti-HB, and anti-e); (3) anti-HBc-Rhodamine (mol F/P-ratio 3-5); (4) anti-e-FITC (2+ positive by immunodiffusion, mole F/P-ratio 2-9, negative for anti-HBs, weakly positive for anti-HBc: 1 :100 in the immune-adherence-haemagglutination-test): anti-eRhodamine (mol F/P-ratio 3 2). Two FITC conjugated anti-e sera of human origin were used simultaneously with identical results. The anti-e serum samples were taken from healthy HB,Ag carriers-that is, asymptomatic, without biochemical and histological abnormalities. The two anti-e sera had specificities against el as well as e2. The anti-HB, used for conjugation were taken from two HB,Ag positive patients with chronic active hepatitis. These sera were negative for anti-HBs, anti-e, and immunocomplexes. Furthermore, anti-human-IgG-FITC and normal human-IgG-FITC were used for negative controls and the respective unlabelled antisera of all mentioned conjugates for blocking studies. 994
Localisationi of e-antigen in nuclei of hepatocytes in HBsAg-positive liver diseases Anti-e-Rhodamine simultaneously in the same nuclei. However, in a few cells only the e-antigen was present and in others only the HB,Ag. A close association between the e-antigen in serum and HB,Ag in the liver cell nuclei has previously been described (Hess et al., 1977) 
